Summary
Hydrocodone bitartrate (HB) and acetaminophen (APAP) combination products are known to be abused via oral, intranasal, and intravenous self-administration. Benzhydrocodone HCl (KP201) is a prodrug of hydrocodone with limited bioavailability when taken intranasally or intravenously, or taken orally at supratherapeutic doses. This study assessed the abuse liability, relative bioavailability, and safety of KP201/APAP, compared with that of HB/APAP (Norco®), when administered at supratherapeutic oral doses to non-dependent, recreational opioid users. Both KP201/APAP and HB/APAP were generally well tolerated and had similar Drug Liking scores, but KP201/APAP displayed lower peak and cumulative systemic exposure to hydrocodone at high and mid oral doses.
Register to download
Oral Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone
You may also be interested in:
page
Neuroscience & Pain
We provide innovative clinical research solutions for patients and families facing healthcare challenges that include pediatric and rare indications,…
Case Study
Program Challenges Strengthen Partnership
PRA Health Sciences was selected to conduct a global program of studies that targeted 2,200+ patients with multiple sclerosis (MS). Although there…
Poster
Human Abuse Liability Studies: Not Your Traditional Phase I Study
Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’…